Related Experiment Video
Updated: Jan 7, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Non-linear association of coagulation factor XI with mortality
Katsiaryna Prystupa1, Martin Heni2, Sebastian Hörber3
1Institute for Clinical Diabetology, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at Heinrich-Heine University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), Partner Düsseldorf, Neuherberg, Germany.
Coagulation factor XI (FXI) activity shows a U-shaped link to mortality in coronary artery disease (CAD) patients. Higher FXI activity increases mortality risk in CAD, unlike in non-CAD individuals.
Area of Science:
- Cardiovascular Medicine
- Hemostasis Research
- Clinical Trials
Background:
- Coagulation factor XI (FXI) plays a role in thrombosis and myocardial function.
- Understanding FXI's impact on mortality is vital for treating coronary artery disease (CAD).
Purpose of the Study:
- To investigate the association between coagulation factor XI (FXI) activity and mortality risk.
- To explore how CAD and NT-proBNP levels modify this relationship.
Main Methods:
- Analysis of 3,170 participants undergoing coronary angiography, with 67% diagnosed with CAD.
- Median follow-up of 14.5 years, assessing mortality risk using Cox models.
- Exploration of interactions between FXI activity, NT-proBNP, and CAD status.
Main Results:
- A U-shaped association between FXI activity and mortality was observed (p=0.027), with lowest risk at 115.6% FXI activity.
- This U-shaped pattern persisted in patients without CAD.
- In CAD patients, higher FXI activity showed a linear correlation with increased mortality (p-interaction < 0.0001), significantly modified by NT-proBNP levels.
Conclusions:
- FXI activity has a dual role in hemostasis with implications for drug development.
- Treatment strategies targeting FXI may require personalization based on cardiovascular conditions.
- Future FXI inhibitor studies must consider modulating factors like CAD and NT-proBNP for optimized therapies.
Related Concept Videos
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Coagulation
Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Clot Retraction and Fibrinolysis

